TriangleMirvetuximab Soravtansine-gynx (NCT05887609)
Mirvetuximab Soravtansine-gynx trial for Ovary Cancer (NCT05887609). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged eighteen to one hundred with recurrent platinum-sensitive high-grade serous or endometrioid ovarian, peritoneal, or fallopian-tube cancer. Medium/high folate-receptor-alpha expression and controlled disease after platinum are required. BRCA-mutated patients must have received a PARP inhibitor.
The idea: mirvetuximab carries a cell-division-blocking payload; olaparib blocks DNA repair. Maintenance pairs mirvetuximab infusions every three weeks with olaparib tablets twice daily. Researchers measure progression and safety, beginning with six safety patients.
This phase 2 study plans 53 patients. Bradley Corr leads at the University of Colorado, Denver; six US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.